4 月 29 日，据 CNBC 报道，吉利德科学（Gilead Sciences）同意向美国政府和各州支付 2.02 亿美元，以解决其利用演讲项目向医生支付回扣，诱导他们为患者开具昂贵的抗 HIV 药物的民事指控。

Gilead Sciences’ long-acting drug to block HIV has the potential to end the AIDS epidemic worldwide. But accessibility ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...

The MoU establishes a framework for collaboration between ADPHC and Gilead Sciences across two core pillars: disease ...

No significant association was observed between viremia history during ART and CVD risk in a large international cohort of patients with HIV infection.

That shows how the company is now overvalued in our view. The largest risk to our thesis is if Gilead Sciences can achieve ...

Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD ...

A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response ...

As the Trump administration slashes funding for HIV-related research and infrastructure, Gilead, Immunocore and more are targeting the next goalpost: a cure.

The HIV Clinical Trials Market focuses on the systematic evaluation of novel antiretroviral therapies, combination regimens, long-acting injectables, and immunotherapeutic approaches to control and ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street’s revenue expectations in Q1 CY2025, with sales ...

We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we ...